B cell antigen receptor
Activation of the B Cell Antigen Receptor Triggers Reactivation of Latent Kaposi's Sarcoma-Associated Herpesvirus in B Cells
... plasma cell differentiation (23, 24) and gammaherpesviral reactivation (18, ...EBV-infected B cells, reactivation of the lytic cycle can be triggered by activating the B cell antigen ...
13
B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model
... One study using MALT1-/- mice suggested that MALT1 is required for TLR4-induced B cell prolifera- tion [5]. A parallel study did not confirm a defect in TLR4 signaling in MALT1-/- B cells [4]. This ...
9
B cell antigen receptor isotypes : implications for immune memory
... splenic B cell phenotype existed between the three principal lines (GG4, MG2 and MM4) used in this ...mature B cells, as well as varying degrees of receptor editing away from the transgene ...
248
BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
... T cell and B cell functions are involved in the development of autoimmune diseases [2, ...vated B cells function as potent antigen-presenting cells and activate autoreactive T ...on ...
6
Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross sectional study
... hi B-cell sub- type has been ...affect B-cell function by negative regulation of B-cell receptor (BCR) signaling, as well as by inducing the production of IL-10 ...
18
Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases
... foreign antigen is encountered. During antigen recogni- tion, TCR clustering in the central region of the immunologic synapse, a process that evolves over time, would result in functional segregation of ...
7
Cancer biomarkers for targeted therapy
... T cell engagers, and antibody-drug ...CLL-1, B cell maturation antigen, and CD138 are targets for cancer immunotherapeutic agents, including the chimeric antigen receptor - ...
7
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... chimeric antigen receptor-modified T-cell (CAR-T) therapy for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both ...
12
Tumor necrosis factor superfamily member APRIL contributes to fibrotic scar formation after spinal cord injury
... BAFF: B cell-activating factor; BAFF-R: B cell-activating factor receptor; BCMA: B cell maturation antigen; BMS: Basso Mouse Scale; EdU: 5-ethynyl-2 ′ ...
8
Chimeric antigen receptor T cell therapies for multiple myeloma
... CD138, also known as syndecan 1, is a membrane protein and a member of the syndecan family of heparan sulfate proteoglycans. It is an adhesion molecule that binds to the extracellular matrix (ECM) molecules collagen and ...
12
ITAMs versus ITIMs: striking a balance during cell regulation
... of receptor complexes involved in linking the ligand-binding portion of the receptor to the activation of intracellular signaling cascades, including those that contribute to cellular activation and ...
9
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... in B cell lymphoma and leukemia therapy [1, ...chimeric antigen receptor (CAR) – engineered T cells target- ing CD19 has opened a new era with “living drugs” for can- cer immunotherapy ...
5
The role of BCR destabilization in antigen processing
... recognition receptor that serves multiple functions throughout B cell development ...immature B cells express a functional ...induce cell death via apoptosis or receptor editing ...
123
Identification of LCK as a key mediator of B cell receptor (BCR)signalling in chronic lymphocytic leukaemia (CLL)
... the antigen receptor on B and T cells, Toll-like receptors (TLRs) and the Tumour necrosis factor (TNF) ...BAFF receptor and LTβR. Stimulation through these receptors activates ...
197
Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient derived tumours
... to antigen expression on healthy tissues, antigen targets for CAR T cell therapies must be selected for those that are expressed exclusively on the tumour, or in the case of CD19-specific CAR T cells ...
14
B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice
... During B lymphocyte development in the BM, immature B cells expressing self-reactive antigen receptors are tolerized by a vari- ety of ...purges B cells reactive to self antigens from the ...
13
The Role of STAT3 in the Pathogenesis of Chronic Lymphocytic Leukaemia
... mature B cell neoplasms, mature T and NK cell neoplasms, Hodgkin’s lymphoma and multiple myeloma (Swerdlow et ...Mature B cell neoplasms include chronic lymphocytic leukaemia (CLL), one ...
250
Universal CARs, universal T cells, and universal CAR T cells
... This patient-specific autologous T cell production plat- form calls for highly skilled and dedicated facility as well as substantial investment in infrastructure. In addition, it is very time-consuming and ...
9
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
... (5.6 vs 2.3 μM for parental cells) (Additional file 1: Figure S5a).The ibrutinib resistance phenotype of UPN- IbruR cells was not associated to mutations in BTK or PLCG2 genes, which both harbored a wild type sequence ...
14
Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma
... CAR-T also exhibited superior clinical efficacy over ASCT in a subpopulation analysis of patients with IPI scores of at least 3. Previous studies revealed that the IPI score was an unfavorable factor of prognosis ...
13